相关实验视频

Updated: Jan 18, 2026

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients

Published on: November 19, 2019

在AR之外的转移性前列腺癌中确定预后标

Emily Feng¹, Eric Feng¹, Tracy Berg²

¹Department of Radiation Oncology, University of California San Francisco, CA, USA.

|May 23, 2025

概括

全基因组查发现了8个基因,这些基因对前列腺癌细胞生长至关重要,并且与预后不佳有关. 这些基因,包括DHFR和PPM1D,是潜在的治疗标,即使在阿比拉治疗后.

科学领域:

在瘤学瘤学.
遗传学遗传学是一个
药理学药理学是指药理学的学科.

背景情况:

前列腺癌带来了重大的治疗挑战,特别是在转移阶段.
识别新型药物点对于改善患者的治疗结果至关重要.
克里斯普尔/RNAi屏幕为发现癌症漏洞提供了强大的工具.

研究的目的:

通过将功能性基因组查数据与基因表达和临床结果信息相结合,识别前列腺癌中可用药物的标.
精确确定前列腺癌细胞存活所必需的基因,这些基因与不良预后相关.

主要方法:

利用了前列腺癌细胞系的DepMap功能屏幕数据.
集成数据与大型基因表达数据库 (N=1012) 和临床结果.
分析了基因依赖性,表达水平,以及与预后和治疗反应的关联.

主要成果:

确定了8个基因 (CYC,CYP51A1,DHFR,EBP,KIF15,PPM1D,SQLE,UMPS) 具有强烈的细胞系依赖性和与更差的临床预后相关.
四个基因 (DHFR,EBP,KIF15,PPM1D) 在神经内分泌前列腺癌中表达更高.
大多数已识别的基因仍然是可向的后比拉特治疗,这表明克服治疗耐药性的潜力.

结论:

这八个已识别的基因代表了转移性前列腺癌的有希望的治疗点.
这些目标显示出潜在的临床相关性,特别是在神经内分泌前列腺癌和治疗后的环境中.
进一步的研究是有必要的,以探索在前列腺癌治疗中这些可用药物的临床实用性.

关键词:

这里有DepMap,DepMap.临床遗传学临床遗传学前列腺癌是前列腺癌.

更多相关视频

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

Pre-clinical Orthotopic Murine Model of Human Prostate Cancer

Pre-clinical Orthotopic Murine Model of Human Prostate Cancer

Published on: August 29, 2016

相关概念视频

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

mTOR Signaling and Cancer Progression

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...

Mitogens and the Cell Cycle

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...